Navigation Links
Sanomedics International Holdings, Inc. appoints new Chairman of the Board and installs new Director of Business Development.
Date:9/11/2013

MIAMI, Sept. 11, 2013 /PRNewswire/ -- Sanomedics International Holdings, Inc. (OTCQB: SIMH), a Miami based medical technology holding Company that focuses on game changing products, services and ideas, announces that William Lerner, Esq., a board member of the Company since March 2013, has been appointed to serve as the chairman of the executive board of the Company.

Keith Houlihan, Co-founder and President of Sanomedics, stated, "We are fortunate to have someone of Mr. Lerner's caliber as our Chairman. Mr. Lerner will help position us for a listing upgrade and strengthen our corporate governance requirements. He will serve the best interests of the company during this time of growth and we look forward to working with Mr. Lerner."

Mr. Lerner, a graduate of Cornell University and of the New York University School of Law, is a member of the bars of New York and Pennsylvania, with a Peer Rating for more than 25 years of AV (Martindale Hubbell). For over the last five years, Mr. Lerner has been engaged in the private practice of corporate and securities law in New York and Pennsylvania. Since 2006, Mr. Lerner has served as a director/trustee of The Daily Income Fund, a diversified, open-end management investment company, and also serves as the Chairman of the Compliance and Risk Committee. Mr. Lerner also served as Branch Chief of the Enforcement Division at the SEC and a former officer and director of compliance at the American Stock Exchange.

Mr. Lerner is also a director of National Holdings Corporation, a holding company for National Securities Corporation, vFinance Investments, Inc., National Asset Management, Inc. and National Insurance Corporation. National Securities and vFinance are broker-dealers registered with the Securities and Exchange Commission, and members of FINRA and SIPC. National Asset Management is an SEC registered investment adviser, and National Insurance provides a full array of fixed insurance products.

Additionally the Company announces the promotion of Mr. Mark Miklos as General Manager and Director of Business Development for the newly acquired company Prime Time Medical.

"Mark is bringing more than 20+ years of building healthcare businesses, a proven ability to create and pursue new markets", stated Keith Houlihan, Co-founder and President of Sanomedics. "Having Mark will be a valuable asset to the Sanomedics family as we look to expand our market presence through organic and acquired growth."

Mark was the founder and President of Prime Time Medical Inc. since 2009 up to the recent purchase by the Company.  Prior to 2009 he has served as CEO of Respiratory Supply, Pinellas, Florida and Director of Business Development for Diabetic and Respiratory Supply of USA/CCS Medical, in Clearwater, Florida. Mark holds a BS degree in accounting and computer science from Troy State University, in Troy Alabama.

About Sanomedics International Holdings, Inc.

Sanomedics International Holdings, Inc. (SIMH) is a medical technology holding company that focuses on game changing products, services and ideas - a place where physicians, entrepreneurs, and medical companies can work together to drive innovative technologies through concept, development, and ultimately commercialization. We plan to grow our existing business organically and through strategic acquisitions specifically relating to sleep disorder diagnosis treatments. Sanomedics seeks to acquire sleep therapy operating businesses and our strategy is to integrate a portfolio of world-class products and service providers in the growing Sleep Apnea market. Our goal is to provide Sleep Apnea patients with a reliable and integrated "end-to-end" service platform.

Forward Looking Statements
This press release may contain statements which constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the intent, belief or current expectations of the Company, its directors, or its officers with respect to the future operating performance of the Company. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties (for example, the risk that the acquisition of Prime Time is not consummated), and that actual results may differ materially from those in the forward-looking statements as a result of various factors. The Company's periodic filings with the Securities and Exchange Commission should be viewed for a complete understanding of risk and uncertainty.

Contact: Keith Houlihan, 305-433-7814, keith@sanomedics.com


'/>"/>
SOURCE Sanomedics International Holdings, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. DSMs Marcel Lubben to Keynote SCD-iBIOs Second International Forum
2. SCD-iBIO Announces Second International Forum on Commercializing Global Green
3. iLab Solutions to Present SRA International Webinar for Research Administrators
4. MiMedx Plantar Fasciitis Study Published In The Foot & Ankle International Journal
5. RIAO/OPTILAS, ETOP Draw International Photonics Community to Portugal
6. Bayer CropScience Presents on Bee Health and Stewardship at International Pollinator Conference
7. Nerium International Names Krupp Kommunications, Inc. (K2) Public Relations Agency of Record
8. Fortune 500 Company Contracts with Wireless Analytics to Extend Wireless Expense Management & Mobility Management Services Internationally
9. Dyadic International Reports Second Quarter 2013 Financial Results
10. Novus International to Present Scientific Findings on Prebiotics during Aquaculture Europe 2013
11. Mimedx Scientific Study Is Electronically Published in The International Wound Journal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... 22, 2017 MarketNewsUpdates.com News Commentary  ... The traditional ... being pressured as of late due to the rise of ... has a dramatic impact on patient,s quality of life as ... for identifying new forms of opioid formulations that prevent abuse. ...
(Date:3/22/2017)... , March 22, 2017   Boston Biomedical , ... therapeutics designed to target cancer stemness pathways, today announced ... Andrews as Chief Executive Officer, effective April 24, ... Chiang J. Li , M.D., FACP, who has led ... ago. Under his leadership, Boston Biomedical has grown from ...
(Date:3/22/2017)... ... ... Premier executive recruitment firm, Slone Partners, is proud to have been named a Top ... Hunt Scanlon Media is one of the most respected life science publications in the ... sector. , “It is a great honor for Slone Partners to be part of ...
(Date:3/22/2017)... ... March 21, 2017 , ... Proper glycosylation is critical for ... increase and/or decrease in antibody-dependent cellular cytotoxicity or complement-dependent cytotoxicity, there is a ... , To meet this demand, the team at SCIEX has developed a ...
Breaking Biology Technology:
(Date:3/7/2017)... 7, 2017 Brandwatch , the leading social intelligence ... Prince,s Trust to uncover insights to support its reporting, help ... The UK,s leading youth charity will be using Brandwatch Analytics ... get a better understanding of the topics and issues that are ... ...
(Date:3/2/2017)... 2, 2017 Summary This report provides ... its partnering interests and activities since 2010. ... Read the full report: ... since 2010 report provides an in-depth insight into the partnering ... On demand company reports are prepared upon purchase ...
(Date:3/2/2017)... 2017 Australian stem cell and regenerative medicine ... signed an agreement with the Monash Lung Biology Network, ... Institute and Department of Pharmacology at Monash University, ... study to support the use of Cymerus™ mesenchymal stem ... Asthma is a chronic, long term lung condition ...
Breaking Biology News(10 mins):